t(14;22)(q32;q11) translocation involving IGH and IGL acquired at progression of splenic marginal zone lymphoma treated with rituximab, ibrutinib, and obinutuzumab.

Julia T Geyer, Jia Ruan, Michael J Kluk, Liming Bao

Abstract readCase Reports

In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Julia T GeyerDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.

Jia RuanDepartment of Medicine, Weill Cornell Medicine, New York, NY, USA.

Michael J KlukDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.

Liming BaoDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA. bal4006@med.cornell.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Translocations involving immunoglobin (IG) are common in B-cell neoplasms. These IG translocations lead to the disposition of the enhancer or promoter of an IG locus, typically IGH, to a proto-oncogene, resulting in the elevated expression of the cancer gene. IG fusions play an important role in the diagnosis, prognostication, and therapy selection of B-cell lymphomas. A t(14;22)(q32;q11) translocation involving IGH and IGL is rare in lymphomas. We report herein clinicopathological characteristics, response to treatment, and outcomes of a first splenic marginal zone lymphoma case with a t(14;22)(q32;q11) translocation involving IGH and IGL treated with rituximab, ibrutinib, and obinutuzumab. Studies of additional cases are needed to elucidate the potential role of the t(14;22) translocation in lymphomagenesis and prognostication.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsChromosomes, Human, Pair 14Chromosomes, Human, Pair 22Immunoglobulin Heavy ChainsLymphoma, B-Cell, Marginal ZoneSplenic NeoplasmsTranslocation, GeneticAdenineAntibodies, Monoclonal, HumanizedDisease ProgressionHumansPiperidinesProto-Oncogene MasPyrazolesPyrimidinesRituximabAdenineAntibodies, Monoclonal, HumanizedibrutinibImmunoglobulin Heavy ChainsMAS1 protein, humanobinutuzumabPiperidinesProto-Oncogene MasPyrazolesPyrimidinesRituximabIGH and IGLSplenic marginal zone lymphomat(14;22)(q32;q11)Translocation

Identifiers

PMID40014084

DOI10.1007/s00277-025-06282-5

PMCPMC12031878

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.